US Congress demands briefing from Gilead on its pricing strategy for Sofosbuvir (Sovaldi)- new oral drug for Hep-C treatment for which it recently received marketing approval in US.
The Committee of Energy and Commerce, House of Congress asked for providing reasons for pricing the drug at cost of 84,000$ which will be un-affordable for majority of patients in the country. The letter sent to Gilead raised concern on the high cost despite of role played by the Federal Government in speeding up the approval for this drug and the savings arising from this process.
The Committee in specific asked Gilead to share its methodology used to establish price of Sovaldi and the discounts planned for low income patients, key government and private sector purchasers.
Read the full article here